Published in J Clin Oncol on January 26, 2009
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst (2009) 5.40
Cancer drugs in the United States: Justum Pretium--the just price. J Clin Oncol (2013) 4.25
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol (2013) 2.29
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol (2010) 2.10
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol (2014) 1.67
Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol (2013) 1.63
Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol (2013) 1.45
Renal cell carcinoma. BMJ (2014) 1.45
Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer (2011) 1.41
Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer (2011) 1.27
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer (2010) 1.25
Treatment of metastatic renal cell carcinoma. Nat Rev Urol (2010) 1.24
(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist (2010) 1.20
Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol (2012) 1.19
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer (2012) 1.17
Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs (2012) 1.13
Antiangiogenic therapy for cancer: an update. Pharmacotherapy (2012) 1.10
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer (2011) 1.08
Efficacy and safety of sorafenib in advanced renal cell carcinoma patients: Results from a long-term study. Oncol Lett (2012) 1.05
Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov (2016) 1.03
Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008). Br J Cancer (2013) 0.96
Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma. PLoS One (2013) 0.95
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol (2013) 0.95
Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol (2009) 0.94
Targeted therapy in renal cancer. Ther Adv Med Oncol (2009) 0.92
Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Br J Cancer (2013) 0.91
Contemporary Treatment of Metastatic Renal Cell Carcinoma. Oncol Rev (2016) 0.90
A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting. PLoS One (2015) 0.88
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. J Transl Med (2011) 0.87
Future directions in renal cell carcinoma: 2011 and beyond. Hematol Oncol Clin North Am (2011) 0.87
Sequence of treatment in locally advanced and metastatic renal cell carcinoma. Transl Androl Urol (2015) 0.86
Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. Clin Cancer Res (2013) 0.86
Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology (2013) 0.86
Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience. Ther Adv Med Oncol (2011) 0.85
Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol (2012) 0.85
Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma. BMC Cancer (2012) 0.85
Protein kinase C regulates the internalization and function of the human organic anion transporting polypeptide 1A2. Br J Pharmacol (2011) 0.84
Systemic therapy for advanced renal cell carcinoma. Ther Adv Med Oncol (2009) 0.84
Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo. Int J Oncol (2013) 0.83
Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. Biomed Res Int (2015) 0.83
Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis. Int J Clin Oncol (2012) 0.83
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer (2014) 0.83
Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents. Curr Oncol (2012) 0.82
Experience with sorafenib in the treatment of advanced renal cell carcinoma. Ther Adv Urol (2012) 0.82
A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. Br J Cancer (2010) 0.82
Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. Br J Cancer (2013) 0.82
Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib. Clin Med Insights Oncol (2011) 0.82
Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy. J Cancer Res Clin Oncol (2013) 0.81
Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration. Br J Cancer (2013) 0.81
Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol (2010) 0.81
Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials. PLoS One (2011) 0.81
Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies. Oncologist (2010) 0.81
Sorafenib in advanced melanoma: a critical role for pharmacokinetics? Br J Cancer (2012) 0.81
An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma. Ther Adv Urol (2013) 0.81
Comparing comparators: a look at control arms in kidney cancer studies over the years. Br J Cancer (2014) 0.81
Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Oncotarget (2016) 0.81
Sorafenib in the management of metastatic renal cell carcinoma. Curr Oncol (2009) 0.79
Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature. Support Care Cancer (2014) 0.79
Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2). PLoS One (2014) 0.79
Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Support Care Cancer (2013) 0.79
Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). Radiat Oncol (2015) 0.79
New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. J Hematol Oncol (2017) 0.78
Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma. Cancer Manag Res (2011) 0.78
Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis. Exp Ther Med (2015) 0.78
The bevacizumab experience in advanced renal cell carcinoma. Onco Targets Ther (2010) 0.78
Molecularly targeted drugs for the treatment of cancer: oral complications and pathophysiology. Hippokratia (2012) 0.78
Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. Mol Cancer Res (2016) 0.78
Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma. Cancer Cell Int (2014) 0.78
Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer (2016) 0.77
Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy. Cancer Sci (2016) 0.77
Sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol (2016) 0.77
Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma. Open Access J Urol (2011) 0.77
Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study. PLoS One (2015) 0.77
Metastatic renal cell carcinoma: Current scenario and future trends. South Asian J Cancer (2012) 0.77
Treatment of metastatic renal cell carcinoma and renal pelvic cancer. Clin Exp Nephrol (2011) 0.77
Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan. BMC Cancer (2015) 0.76
Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions. Support Care Cancer (2012) 0.76
Pazopanib for the treatment of patients with advanced renal cell carcinoma. Clin Med Insights Oncol (2010) 0.76
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. J Clin Invest (2016) 0.76
An update on current management of advanced renal cell cancer, biomarkers, and future directions. Ann Cancer Res (2015) 0.76
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma. BMC Cancer (2014) 0.76
Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer. Invest New Drugs (2014) 0.76
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implications. Ther Adv Med Oncol (2013) 0.75
Management of metastatic renal cell carcinoma - mini review. J Kidney Cancer VHL (2015) 0.75
Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy. Cancer Res Treat (2016) 0.75
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. Eur Urol (2016) 0.75
Individualising treatment choices in a crowded treatment algorithm. EJC Suppl (2013) 0.75
Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next? Ann Transl Med (2016) 0.75
Complete response to low-dose sorafenib in a patient with metastatic renal cell carcinoma: A case report. Can Urol Assoc J (2013) 0.75
Case report demonstrating effectiveness of sorafenib in multiple lung and bone metastases of renal cell carcinoma. Oncol Lett (2015) 0.75
Prolonged survival after sequential multimodal treatment in metastatic renal cell carcinoma: two case reports and a review of the literature. J Med Case Rep (2012) 0.75
Study design and clinical evidence in mRCC: can we save axitinib as a first-line therapy? Cancer Biol Ther (2014) 0.75
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Med (2014) 0.75
Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. Clin Genitourin Cancer (2015) 0.75
RNA interference-mediated silencing of speckle-type POZ protein promotes apoptosis of renal cell cancer cells. Onco Targets Ther (2016) 0.75
Chinese guidelines on the management of renal cell carcinoma (2015 edition). Ann Transl Med (2015) 0.75
Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. Ther Adv Urol (2015) 0.75
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care (2007) 12.71
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain (2007) 8.89
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med (2004) 8.60
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol (2014) 6.64
Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol (2007) 6.24
Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy--Spiritual Well-being Scale (FACIT-Sp). Ann Behav Med (2002) 5.69
The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes (2003) 5.58
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol (2011) 5.43
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2007) 5.10
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol (2009) 5.05
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol (2002) 4.69
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol (2012) 4.58
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol (2007) 4.40
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet (2006) 4.26
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS®): depression, anxiety, and anger. Assessment (2011) 4.21
Representativeness of the Patient-Reported Outcomes Measurement Information System Internet panel. J Clin Epidemiol (2010) 4.18
Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol (2002) 4.16
Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res (2009) 4.13
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol (2004) 3.85
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol (2013) 3.79
Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. Value Health (2008) 3.68
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes (2007) 3.66
Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol (2012) 3.65
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol (2012) 3.65
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol (2004) 3.57
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol (2013) 3.48
A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof (2005) 3.43
Assessment of neurological and behavioural function: the NIH Toolbox. Lancet Neurol (2010) 3.20
Sunitinib efficacy against advanced renal cell carcinoma. J Urol (2007) 3.14
Item response theory analyses of physical functioning items in the medical outcomes study. Med Care (2007) 3.10
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol (2008) 3.00
Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol (2005) 2.98
Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol (2007) 2.97
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol (2009) 2.88
Development of a PROMIS item bank to measure pain interference. Pain (2010) 2.85
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol (2009) 2.82
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol (2012) 2.56
Efficiency of static and computer adaptive short forms compared to full-length measures of depressive symptoms. Qual Life Res (2009) 2.55
General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof (2005) 2.51
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer (2013) 2.51
Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol (2006) 2.50
Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes (2006) 2.48
Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain. Pain (2007) 2.47
Laser therapy for upper urinary tract transitional cell carcinoma: indications and management. Eur Urol (2008) 2.43